Category In The News
With the support of many friends, co-workers and family, our team has raised over $59,000 for brain tumor research.
The Phase II trial is led by Dr. Duane Mitchell, director of the UF Brain Tumor Immunotherapy Program.
Key industry and foundation leaders were invited to share their disruptive ideas on the future of neurosurgery at the new CNS Neurosurgery Innovations Symposium.
A letter to the brain tumor community from Max Wallace, CEO of Accelerate Brain Cancer Cure.
The Oct. 10 issue of Cell looks at the progress made by The Cancer Genome Atlas since its launch five years ago.
While the honorees expressed gratitude for the prize, their comments about their work were tinged with worry about the future of biomedical research after years of cuts in federal funding.
The researchers caution that many treatments have cured cancers in mice and then failed in humans. But they are encouraged by the new findings and want to work quickly to design a clinical trial for humans.
Accelerate Brain Cancer Cure helped fund the Phase 2 trial led by Dr. Andrew Parsa, Chair of Neurosurgery at Northwestern Memorial Hospital.
Researchers found that there was a “highly significant” increase in GBM patient survival in the year after Avastin was approved.
Accelerate Brain Cancer Cure was an early investor in Agios to support its novel research into IDH1 gene mutation in brain cancer.